EUVIMEDEUVIMED entdecken
Crossref

Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism

Shi Qiu, Shifa Qiang, Zhibo Wang, Lihua Yang, Sifan Guo, Jiahan Zeng, Ying Cai, Zhicheng Lai, Dandan Xie, Li Che, Aihua Zhang

Journal of Ethnopharmacology · 2027

DOI: 10.1016/j.jep.2026.122201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2027. Verfasst von Shi Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Traditional Chinese Medicine Innovation…. Hauptthemen laut MEDLINE: Bile Acids and Salts, NF-kappa B, Receptors, Cytoplasmic and Nuclear, Drugs, Chinese Herbal. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Hainan Province, Hainan Provincial Department of Science and Technology, Hainan Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ETHNOPHARMACOLOGICAL RELEVANCE: Babaodan (BBD) is a traditional Chinese medicinal formula originating from a Ming Dynasty prescription. It has long been clinically applied in China for liver disorders, yet its systemic mechanism against metabolic dysfunction-associated steatotic liver disease (MASLD) remains poorly understood. AIM OF THE STUDY: To decipher the multi-target mechanism by which BBD ameliorates MASLD, with a focus on the integration of bile acid homeostasis and inflammatory signaling, and to identify the key therapeutic axis underlying its hepatoprotective effects. MATERIALS AND METHODS: A multi-omics approach was employed, combining single-cell transcriptomics of MASLD mouse livers, untargeted serum metabolomics, targeted liver proteomics of bile acid metabolism-related proteins, and network-based integrative analysis. Functional validation was performed in palmitic acid-treated AML12 hepatocytes and a high-fat diet-induced mouse MASLD model. Western blotting and biochemical assays assessed key pathway components and biomarkers. RESULTS: Single-cell transcriptomics identified hepatocytes as the principal hub where bile acid disruption and NF-κB-driven inflammation accumulation, with FXR as a central dysregulated node. BBD dose-dependently alleviated hepatocyte steatosis, apoptosis, and inflammation. Serum metabolomics showed BBD normalized 17 of 24 MASLD-associated metabolites, with bile acid biosynthesis as the most restored pathway. Targeted proteomics revealed coordinated regulation of bile secretion-related proteins, and multi-omics network analysis identified SLC22A7 as a central hub correlated with bilirubin, insulin, and inflammatory mediators. Functional validation confirmed that BBD treatment was associated with upregulation of FXR and SLC22A7, suppression of NF-κB p65 phosphorylation, and reduction of IL-6, identifying these molecules as interconnected features of the therapeutic response. CONCLUSIONS: BBD alleviates MASLD via co-modulation of the FXR, NF-κB, and SLC22A7, restoring bile acid homeostasis and reducing inflammation. These findings reveal BBD as a multi-target agent and provide support for its clinical application in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Acids and SaltsNF-kappa BReceptors, Cytoplasmic and NuclearDrugs, Chinese HerbalFatty LiverAnimalsReceptor, Farnesoid X-ActivatedMiceMaleMice, Inbred C57BLHepatocytesCell LineDiet, High-FatSignal Transduction

Stichwörter der Autor:innen

BabaodanBile acid metabolismFXR/NF-κB/SLC22A7 axisInflammationMetabolic dysfunction-associated steatotic liver disease

Substanzen

Bile Acids and SaltsNF-kappa BReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Traditional Chinese Medicine Innovation and Translation Laboratory, School of Traditional Chinese Medicine, E…
  • Xiamen Traditional Chinese Medicine Co., Ltd., Xiamen, 361100, China.
  • Xiamen Traditional Chinese Medicine Co., Ltd., Xiamen, 361100, China. Electronic address: cl@dinglu.com.cn.

Förderung

  • Natural Science Foundation of Hainan Province
  • Hainan Provincial Department of Science and Technology
  • Hainan Medical University

Zitieren

APA

Qiu, S., Qiang, S., Wang, Z., Yang, L., Guo, S., Zeng, J., Cai, Y., Lai, Z., Xie, D., Che, L., & Zhang, A. (2027). Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2026.122201

Vancouver

Qiu S, Qiang S, Wang Z, Yang L, Guo S, Zeng J, et al. Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism. Journal of Ethnopharmacology. 2027. doi:10.1016/j.jep.2026.122201

BibTeX
@article{Qiu2027,
  author = {Qiu, Shi and Qiang, Shifa and Wang, Zhibo and Yang, Lihua and Guo, Sifan and Zeng, Jiahan and Cai, Ying and Lai, Zhicheng and Xie, Dandan and Che, Li and Zhang, Aihua},
  title = {Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism},
  journal = {Journal of Ethnopharmacology},
  year = {2027},
  doi = {10.1016/j.jep.2026.122201}
}
Kostenlos starten →